According to a recent KPMG report, the global M&A landscape in 2024 signals a rebound despite challenges like geopolitical tensions, high interest rates, and persistent inflation for much of the year.

U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...

Farallon presses Astellas to cut costs and overhaul drugs research in latest shareholder campaign gripping Tokyo ...

M&A markets don't like volatility and unpredictability, and what we've seen in the past few weeks is the opposite of that,” ...

M&A markets don't like volatility and unpredictability, and what we've seen in the past few weeks is the opposite of that,” ...

Novartis is paying $925 million upfront to acquire Anthos Therapeutics, whose launch the pharma backed in February 2019.

As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...

Mitsubishi Chemical Group Corp. (MCG; Tokyo) announced that it has decided to transfer its consolidated subsidiary Mitsubishi Tanabe Pharma Corp. (MTPC; ...

Bain Capital, a global private investment firm, has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma ...

Chemical companies in the US and Europe began exiting the pharmaceutical industry in the mid-1990s, when the British firm ICI ...

The carve-out acquisition will allow Bain to capitalize on the “promising signs for growth” in the Japanese life sciences ...

Tanabe Pharma focuses on therapeutic areas such as immunology and inflammation, vaccines, diabetes, and central nervous ...